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CAV: cardiac allograft vasculopathy 
CMR: cardiac magnetic resonance  
CTx: cardiac transplantation  
ECV: extracellular volume fraction 
HC: healthy controls 
HVBH: hyperventilation followed by breath hold 
ICC: intraclass correlation coefficient 
ISHLT: International Society for Heart and Lung Transplantation 
LGE: late gadolinium enhancement  
OS-CMR: oxygenation sensitive cardiac magnetic resonance 
SI: signal intensity 













Background: Coronary vascular function is related to adverse outcomes following cardiac 
transplant (CTx) in patients with or without coronary allograft vasculopathy (CAV). The 
noninvasive assessment of the myocardial vascular response using oxygenation-sensitive cardiac 
magnetic resonance (OS-CMR has not been investigated in stable long-term CTx recipients).  
Methods: CTx patients were prospectively recruited to complete a CMR study with a breathing 
maneuver of hyperventilation followed by a voluntary apnea. Changes in OS-sensitive signal 
intensity reflecting the myocardial oxygenation response were monitored and expressed as % 
change in response to these breathing maneuvers. Myocardial injury was further investigated with 
T2 weighted imaging, native and postcontrast T1 measurements, extracellular volume 
measurements and late gadolinium enhancement.  
Results: Forty-six CTx patients with (n=23) and without (n=23) CAV, along with 25 healthy 
controls (HC) were enrolled.  The OS response was significantly attenuated in CTx compared to 
HC at the 30s time point into the breath hold (2.63±4.16% vs. 6.40±5.96% P = 0.010). Compared 
with HC, OS response was lower in CTx without CAV (2.62±4.60%, P<0.05) while this response 
was further attenuated in patients with severe CAV (grades 2-3, -2.24±3.65%). An inverse 
correlation was observed between OS-CMR, ventricular volumes and diffuse fibrosis measured by 
extracellular volume mapping. 
Conclusion: In heart transplant patients, myocardial oxygenation is impaired even in the absence 
of cardiac allograft vasculopathy suggesting microvascular dysfunction. These abnormalities can 











Cardiac allograft vasculopathy (CAV) is one of the leading causes of long-term mortality following 
cardiac transplant (CTx).1 This condition is characterized by diffuse and concentric thickening of 
epicardial and intramyocardial graft vessels2 and is associated with endothelial lesions, smooth 
muscle cell proliferation, and pro-inflammatory circulating cell accumulation in the intima, leading 
to myocardial injury without apparent epicardial coronary artery disease.3 Microvascular 
dysfunction with a decrease in coronary flow reserve can occur before overt epicardial coronary 
artery disease4 and has been identified as an independent prognostic factor after heart 
transplantation.5  
ISHLT guidelines recommend screening for CAV annually after heart transplantation.6 There 
are a variety of currently available diagnostic tools available to investigate macro- and 
microvascular dysfunction, all of which have individual advantages and limitations.7 Coronary 
angiography is used for identifying coronary artery stenosis, and this technique may be 
supplemented by intravascular ultrasound, optical coherence tomography, and intracoronary 
Doppler flow measurements.8 However these diagnostic tools are invasive, require radiation, and 
the use of nephrotoxic contrast agents, and do not assess myocardial oxygenation. Endomyocardial 
biopsy displays dysfunction at a cellular level, but is limited by sampling error, does not allow the 
overall assessment of the microvascular myocardial network, and its role for surveillance of grafts 
older than six-months posttransplant is limited.9 Finally, nuclear imaging uses radioactive tracers, 
and the assessment of coronary flow reserve using contrast enhanced echocardiography10 may be 
limited by acoustic windows.  
Oxygenation-sensitive (OS) cardiac magnetic resonance (OS-CMR) allows the assessment of 
changes in myocardial oxygenation. The signal intensity in OS-CMR images is modulated by the 










and thus acts as a marker for myocardial tissue oxygenation.10,11 These changes reflect the 
modification of coronary blood flow and the coronary vascular capacity to vasodilate in the case 
of increased oxygen demand. Thus, neither radiation nor a contrast agent is required for OS-CMR, 
and breathing maneuvers could replace pharmacological vasodilators.  We have previously shown 
that hyperventilation followed by a breath-hold (apnea) induces a significant vascular response due 
to changes in CO2.
12 OS-CMR can demonstrate an attenuated regional response in the presence of 
coronary artery stenosis, but also a more diffuse abnormality that is not associated with 
macrovascular disease. As shown in a previous coronary artery disease cohort, OS-CMR was 
attenuated in myocardial territories irrigated by recently reperfused yet nonstenotic coronary 
arteries, suggesting this response was indicative of microvascular injury.13 Furthermore, in addition 
to assessing the myocardial function, the multi-parametric nature of CMR allows for a 
comprehensive structural evaluation of the heart. As such, the parameters of ventricular function, 
and tissue characteristics like edema, regional and diffuse fibrosis may be assessed using the same 
examination. 
The overall objective of this study was to evaluate the changes in myocardial oxygenation as 
a marker for microvascular function with OS-CMR using specific breathing maneuvers to trigger 
some vasoactive responses in a population of long-term CTx recipients, compared with healthy 
controls (HC). 
Methods 
In this prospective, single-center, nonrandomized, mechanistic investigation, we enrolled 
stable, adult (age above 18) patients, 6 or more months after orthotopic CTx.  Clinical stability was 
confirmed by 1 of the transplant cardiologists. To assess for the presence and severity of CAV, a 
coronary angiogram was completed before enrolment as per best clinical practice. Healthy controls 










factors. HC’s found to have abnormal left ventricular function or volumes by CMR were excluded 
from the final analyses. General exclusion criteria were known contraindications to CMR (e.g. 
metallic implants), pregnancy, a glomerular filtration rate below 45mL/min/1.73m2, claustrophobia 
or any clinically significant respiratory disease.  All participants gave informed consent.  The study 
was approved by the Montreal Heart Institute Ethics Committee (number 13-1444). 
CMR Protocol 
CMR exams were performed using a clinical 3 Tesla MRI system (MAGNETOM Skyra; 
Siemens Healthcare, Erlangen, Germany). Detailed imaging parameters are provided in the 
supplementary information (Text S1 http://links.lww.com/TP/B989 ). All participants were asked 
to refrain from consuming food containing caffeine for 12 hours prior to the exam. The participants 
watched a training video before the CMR examination. The breathing maneuver protocol consisted 
of 60 seconds of paced hyperventilation at a rate of 30 breaths/min and a subsequent long breath-
hold. During hyperventilation, the patients were monitored through live video feed and were 
instructed to modify their breathing pattern if the rate or depth was inadequate. After 60 sec of 
hyperventilation, the patients were instructed to hold their breath in an end-expiratory position until 
they felt the need to breathe, which they indicated by squeezing an alarm ball.12 During the breath-
hold, OS images were acquired continuously in 2 short-axis slices. The imaging protocol also 
included cine images in short axis stacks and 6 long axis views for LV function. T2-weighted short-
tau inversion recovery images (STIR) were acquired in 3 short-axis views for the assessment of 
edema. T1 maps were acquired in the same planes before and 20 minutes after a 0.1mmol/kg 
intravenous bolus of gadobutrol (Gadovist™, Bayer Inc., Leverkusen, Germany). These T1 maps 
were subsequently used for the calculation of extracellular volume (ECV) as a marker for diffuse 










visualizing focal fibrosis/necrosis. Following the exam, all participants completed a questionnaire 
on their experience, including side effects. 
CMR Image Analyses 
CMR analyses were performed in a blinded fashion, using certified software (Circle CVI, 
Calgary AB, Canada). Ventricular volumes were calculated by tracing epicardial and endocardial 
contours at end-systole and end-diastole, including trabeculae and papillary muscles into the 
myocardial mass. OS-CMR in end-systolic phases and T1 mapping images were analysed using 
simplified epicardial and endocardial contours (excluding trabeculae and papillary muscles). The 
OS response was quantified as percent change to the beginning of the breath-hold. The time point 
closest to 30 seconds into the breath hold was used for the primary statistical analysis. The 
observations computed at the very end of apnea are provided in the supplemental material 
http://links.lww.com/TP/B989 . For assessing inter-observer variability, a second experienced 
reader evaluated images from 14 random CTx patients. ECV was calculated from myocardial and 
blood pool measurements of the native and post contrast T1 map and hematocrit. When LGE was 
present, the % scar per total myocardial volume was measured using a 3 SD approach from a 
reference myocardial contour. From the T2 STIR images, a ratio was obtained for the myocardial 
signal in comparison to a reference skeletal muscle. For all myocardial sequences, measurements 
are reported as a single global value. 
Statistical Analyses 
Continuous variables are presented as mean ± standard deviation or median [lower and upper 
quartile] and nominal variables are presented as counts and frequency (%). Intergroup comparisons 
were performed using univariate linear models for parametric variables and Kruskal-Wallis test or 
chi-square for nonparametric ones. Pearson’s or Spearman’s correlation coefficient analysis were 










Inter-observer reliability was determined with an intra-class correlation (ICC) based on single 
measures using a two-way mixed model assessing absolute agreement for global oxygenation (OS) 
response. Statistical analysis was performed using GraphPad Prism version 8.0 (GraphPad 
Software, La Jolla California USA) and the Statistical Package for Social Sciences version 25 
(SPSS IBM, Chicago, IL, USA).  A P value of less than 0.05 indicated statistical significance. 
Results 
Study Population  
The study population included 46 CTx patients and 25 HC. Seven CTx patients (15%) and 2 
HC (8%) were excluded from the OS-CMR analysis because of breath-hold shorter than 30 seconds 
or insufficient OS-CMR image quality. Clinical characteristics of the study population are 
presented in Tables 1 and 2. Median time since CTx was 7.6 years, with a mean recipient age of 
59±11 years and a graft age of 45±15 years at the time of the CMR exam. Among CTx patients, 
23 (50%) presented with no CAV, 17 (37%) with CAV grade 1, and 6 (13%) with CAV grade 2 
and 3. A cellular rejection score was calculated according to Liang et al14 as the sum of all rejection 
grades (1R=1, 2R=2, 3R=3) from the biopsies divided by the total number of biopsies taken from 
transplant until the date of CMR. The mean rejection score for the CTx patients was less than 1 
(0.68 ± 0.35), with only 6 (13%) patients having a mean rejection score of 1.0 or greater.  
CMR Ventricular Function and Tissue Characterization 
CMR results are presented in Table 3. Compared with HC, CTx exhibited smaller end-diastolic 
left ventricular volumes, smaller ejection volumes, and lower ejection fractions. ECV as a marker 
for diffuse fibrosis was significantly higher in CTx patients. LGE corresponding to areas of 
regional fibrosis or scar, was present in 25 (54%) of CTx patients. Areas of LGE enhancement (15, 
33%) were primarily at the septal insertion points of the right ventricle, while 4 (9%) reflected 










present in all patients with grade 2 and 3 CAV, and additional findings in relationship with CAV 
status are presented in Table S1.  Furthermore, 6 (13%) patients yielded a globally elevated T2 
STIR ratio above 2.0.  
Myocardial Oxygenation Response 
The breathing maneuvers were well tolerated by all CTx patients (100% ability to perform 
maneuvers), while 91% were able to maintain a 30sec breath-hold. Side effects such as dizziness 
or chest oppression occurred in 9% of patients. Of the 3264 myocardial segments from the OS 
images, 3074 (94%) could be analysed. Hyperventilation increased heart rate in both CTx (+7 ± 
5bpm, P < 0.001), and HC (+20 ± 11bpm, P < 0.001, Figure S1), There was a good inter-observer 
agreement (ICC 0.89, 95%CI: 0.78-0.95, P < 0.001). The percent change in OS signal was 
significantly attenuated in the CTx population compared with HC at 30 seconds into the breath-
hold (2.63±4.16% vs. 6.40±5.96% P = 0.010, Figure 1). The evolution of the OS response over the 
breath-hold is presented in Figure 2 while some selected and representative images are illustrated 
in Figure 3.  
The presence or absence of CAV yielded some significant effect on the OS-response in CTx 
patients at 30s (P = 0.026, Figures 1 and 2). Follow-up analysis for multiple comparisons 
demonstrated that the global OS response for patients with severe CAV (grade 2 and 3, -2.2 ± 
3.6%) was significantly attenuated in comparison to CTx with minimal CAV (grade 1, 3.9 ± 2.6%, 
P = 0.022). There was a nonsignificant trend observed between the CTx recipients with severe 
CAV versus those without CAV (2.6 ± 4.6%, P = 0.054), while no difference was computed 
between grade 1 CAV versus no CAV (P = 0.327). OS responses at the very end of the breath-hold 
reported similar findings for the impact of CAV (Figure S2). Other potential confounders such as 











Association of Myocardial Oxygenation Response with Other CMR Markers 
The relationships between the OS response and some structural myocardial parameters are 
presented in Table 5. Univariate analysis demonstrated that an attenuated OS response was 
associated with an increased ECV (r = -0.352, P = 0.030) a measure of diffuse myocardial fibrosis, 
but not with the presence of LGE. In patients without any LGE, the OS response was 3.5 ± 4.8%, 
2.1 ± 3.2% in patients with insertion point enhancement, and 1.5 ± 3.7% in patients with other 
myocardial enhancement (midwall, sub-endocardial and sub-epicardial, P = 0.411). An inverse 
correlation was also observed between OS-CMR and the left ventricular end-diastolic volume 
index (r = -0.445, P = 0.007) and stroke volume index (r = -0.336, P = 0.049), while a nonsignificant 
trend was observed between the OS response and donor age (r = -0.293, P = 0.070).   
Discussion 
In this study, we reported a markedly decreased myocardial oxygenation response in cardiac 
transplant patients in comparison to healthy controls using breathing maneuvers as vasoactive 
stimuli. This finding was observed for both patients with and without CAV, and thus was most 
likely due to a diminished coronary vasoreactivity. Patients with advanced CAV exhibited a more 
severe impairment in myocardial oxygenation response compared with patients without CAV. In 
addition, we observed a significant inverse relationship between the OS response and LV size as 
well as with the degree of diffuse myocardial fibrosis. This study showed that coronary vascular 
function can be safely assessed using OS-CMR in stable CTx recipients. 
This investigation is clinically relevant in the context of the adverse prognosis associated with 
microvascular dysfunction following CTx,5 as well as the high prevalence of asymptomatic CAV 
following CTx. Annual screening for myocardial ischemia is recommended but repetitive coronary 
angiographies carry a risk of vascular access complications and exposure to excessive doses of 










coronary vascular function in relationship with the presence and/or the magnitude of CAV.16,17 
Noninvasive myocardial stress perfusion studies using adenosine, may cause prolonged heart block 
in CTx recipients because cardiac denervation increases sensitivity to this drug.18 Recently, 
Kazmirczak et al reported the safety of stress perfusion CMR using regadenoson in CTx.19 They 
also reported that an abnormal stress perfusion was associated with a 3-year cumulative incidence 
of 32.1% for major adverse cardiovascular events vs 12.7% in CTx patients with a normal stress 
perfusion, demonstrating the benefit of testing the vascular function.19 The high prevalence of renal 
insufficiency after CTx (approximately 20%) limits the use of iodinated and gadolinium-based 
contrast agents.20,21 However, recent data has reported that group II gadolinium-based contrast 
agents are safe,22 even in patients with stage 4 or 5 chronic kidney disease. To the best of our 
knowledge, our study is one of the first to investigate changes of myocardial oxygenation using a 
noninvasive, nonradiating, and nonpharmacological albeit developing technique.  
It is well known that CO2 affects the coronary vascular system.
23,24 More recently, it has been 
shown that the impact of breath-holding and hyperventilation on CO2 allows for their use as a 
significant coronary vasoactive stimulus. Apnea triggers hypercapnic vasodilation, while 
hyperventilation induces hypocapnia and subsequent vasoconstriction.23,25 A previous 
investigation has demonstrated that an apneic stimulus could identify differences in myocardial 
oxygenation (T2 and T2*) between patients with hypertension and controls.26 A combined 
breathing maneuvers of 60sec hyperventilation followed by spontaneous continuous breath hold 
(HVBH) used here has been previously validated for this purpose in swine27 and in healthy human 
volunteers,28 obstructive sleep apnea,29 and coronary artery disease.13  We have focused on the 30s 
time-point because the majority of patients can hold their breath for 30s following proper 
hyperventilation.30 This technique and the 30s time-point have been compared to pharmacological 










with intravenous adenosine.12 The healthy control group in the current study yielded an increase in 
signal, or luxury oxygenation, while CTx recipients demonstrated an attenuation in signal, with 
15% of patients having a global myocardial deoxygenation during the vasodilating HVBH stimulus 
indicated by a drop in signal. It is also known that hyperventilation increases heart rate31 similar to 
adenosine,12 but to a lesser extent in patients with cardiovascular disease than in age-matched 
controls.32 We observed a similar trend in our CTx patients, although it is unknown how the 
increased heart rate modulates the OS response. 
In this study, 50% of CTx recipients presented with some degree of CAV. While the 
attenuation of the OS response was more pronounced in advanced CAV, it was also present in 
patients without CAV when compared to HC. This finding is likely related to an impairment in 
coronary microcirculation that may occur before the development of epicardial coronary disease 
diagnosed on angiography.4 Similarly, myocardial OS responses to adenosine are known to have a 
prognostic value in patients with chronic kidney disease,33 and are impaired in renal transplant 
recipients in the absence of myocardial scarring and other potential confounders, suggesting 
microvascular disease in these patients as well.34  
In this study, we reported no association between OS response and LGE, a measure of focal 
myocardial fibrosis. However, there was a significant relationship between OS response and ECV, 
a marker of diffuse myocardial fibrosis and ventricular remodeling. A previous investigation has 
shown that LGE was associated with an increase long-term risk for major adverse cardiac events 
and death in CTx recipients.35 In the present study, LGE enhancement was not highly prevalent, 
with only 10 patients having myocardial enhancement beyond the ventricular insertion points. As 
such, the data heterogeneity and the small sample size likely explain the discrepancy in LGE 
findings in previous studies. On the other hand, some reports have shown that extracellular volume 










transplantation.36,37 Here we reported that myocardial OS response was associated with ECV 
findings. These observations, and more specifically the fact that OS abnormalities were observed 
in patients without CAV, support the concept that OS responses most likely reflect some significant 
dysfunction of the microcirculation in the human cardiac allograft. Indeed, the presence of 
periarteriolar fibrosis on histology is a characteristic of micro-vasculopathy after CTx.38 The 
magnitude of fibrosis and VEGF increase in parallel up to 5 years after CTx followed by an isolated 
continuous rise in fibrosis suggesting a relative deficit in VEGF, and thus a deficient angiogenesis 
process in older grafts.39,40 In addition, long standing systemic hypertension, abnormal coronary 
vasomotion related to cardiac denervation, and the presence of other pro-atherosclerotic conditions 
such as the metabolic syndrome and diabetes may contribute to these findings and the progression 
of microvascular disease. The advantage of CMR is that the data provided by OS-CMR may be 
analyzed in the context of other parameters for tissue characterization and the assessment of cardiac 
function, thus providing a comprehensive assessment of the allograft. Nevertheless, as OS-CMR 
is an emerging technique, more studies are needed to confirm the association between OS imaging 
in response to breathing maneuver with other techniques for the evaluation of microvascular 
disease. 
Limitations 
This investigation is the first study reporting on breathing maneuvers in combination with OS-
CMR in this specific population. As such, the observations presented here could not be compared 
with our previous results using pharmacological-mediated vasodilation such as adenosine. 
Similarly, we could not validate these observations with other well-validated invasive measures of 
microvascular function, quantitative coronary angiography, and histology. Furthermore, the sample 
size was small, specifically for patients presenting with grade 2 and 3 CAV.  Further studies 










for the diagnosis and prognosis of CAV following CTx. Similarly, low rejection scores were 
observed in this cohort and the association between rejection and OS-CMR data could not be 
assessed. Finally, other relevant parameters such as the evaluation of cardiac tissue for the presence 
of antibody-mediated rejection and/or the measure of donor specific antibodies were not performed 
in these stable long-term patients post CTx.   
The data presented here are based on the 30s time-point assessment, which is a breath-hold 
duration achievable by 91% of patients. Our previous studies show that earlier time-points may 
still provide useful information for these patients who do not have the ability to hold their breath. 
T2 STIR sequences were used for the assessment of edema. This sequence has a lower reader 
reproducibility and is only semi-quantitative relying on comparisons to reference muscle, which 
may have its own signal elevation. Advancements in quantitative T2 mapping may overcome the 
limitations posed by the T2 inversion recovery sequences applied in this study, thus allowing for a 
better assessment of diffuse myocardial edema. The various immunosuppressive regimens and 
anti-hypertensive drugs were not standardized and only CTx recipients were treated with 
immunosuppressive medications. Some of these drugs including rapamycin modulate coronary 
vascular function. In addition, HC were significantly younger and thus, age may have confounded 
our observations.  
Conclusion 
Long-term stable CTx recipients exhibit a significant attenuation in cardiac vascular reactivity 
in response to pCO2 modulation as reflected by the myocardial oxygenation response. OS-CMR in 
combination with tissue characterization and a comprehensive cardiac imaging examination may 
be useful to monitor these high-risk patients, and could assist clinicians in deciding the optimal 
timing for invasive testing post transplantation. Additional investigations recruiting a larger 









up are needed to better understand the mechanisms involved and the long-term clinical impacts of 
these findings. 
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Figure 1. Mean ± SD are shown for the OS response to a long-breath-hold. (A) Healthy controls 
(green) had a significantly larger OS response than the CTx group (black). (B) Additional analysis 
showed that the presence of CAV had a further attenuating impact on the OS response.*P<0.05.  
Figure 2. Myocardial oxygenation response to a long breath-hold. (A) Global response of healthy 
controls (green) and all CTx patients (black). (B) Patients with grade 1 CAV had a similar response 
as those without CAV while those with CAV grade 2 or 3 exhibited an oxygenation deficit. Curves 
are truncated at the mean ± 1SD breath-hold duration of the selected patients. (C) The CTx response 
was also categorized by extracellular volume into 3 groups, based on the range of mean ± 1SD of 
healthy controls ECV measurements, or between mean ± 1SD and mean ± 2SD, or greater than 
mean ± 2SD. The curves were cut at the mean ± 1SD end breath-hold time of the group. 
Figure 3. CMR results are shown of a 4-chamber cine, the myocardial oxygenation (OS) response 
at 30s into the breath-hold in end-systole, along with a native T1 map, an extracellular volume 
(ECV) map, and the late gadolinium enhancement image (LGE) obtained in end-diastole. (A) OS, 
T1 and ECV from a healthy control yield values within the normal ranges (green). (B-E) 
demonstrate the different patterns observed in CTx patients. Patient B yielded similar results to the 
healthy control. While C shows a patient without CAV who had a global oxygenation abnormality, 
with higher ECV in the septum (red). D and E demonstrate regional OS deficits (blue) and higher 










TABLE 1. Demographic characteristics of CTx patients and healthy controls. 
   CTx 
n=46 
HC 
n=25 P value 
Age (years) 59.1 ± 10.6 46.5 ± 8.1 <0.001 
Gender (male) 38 (83%) 16 (64%) 0.090 
Donor age (years) 35.1± 15.2 NA  
Donor gender (male) 30 (65%) NA  
Time since transplant (years) 7.6 (4.3 – 14.5) NA  
Graft age (years) 45.0 ± 15.3 NA  
Ischemic time (minutes) 122 (90 – 194) NA  
Height (cm) 170 ± 10 173 ± 10 0.143 
Weight (kg) 77.5 ± 16.3 78.7 ± 14.5 0.764 
Body mass index (kg/m2) 27.8 ± 8.7 26.0 ± 2.8 0.320 
Systolic blood pressure 
(mmHg) 
115.7 ± 10.9 116.4 ± 8.2 0.784 
Diastolic blood pressure 
(mmHg) 
74.0 ± 9.1 77.2 ± 7.5 0.164 
Heart rate (bpm) 79 ± 9 68 ± 7 <0.001 
Mean ± SD, median (interquartile range) or frequency and the proportion of the group, n(%) are 










TABLE 2. Clinical conditions and treatment of CTX patients. 
Etiology of CMP pre-CTx 
  Dilated 
  Ischemic 
  Viral 
  Others ¥ 
 
 10 (22%) 
 18 (39%) 
 9 (20%) 
 9 (20%) 
Diabetes pre-CTx / at inclusion  8 (17%) / 14 (30%) 
Hypertension pre-CTx / at inclusion  10 (22%) / 29 (63%) 




104 ± 24 
Mean eGFR (mL/min/1.73m²) 
< 30* 
30 – 59 
60 – 89 
≥ 90 





Smoking habits  3 (7%) 
Mean rejection score    0.68 ± 0.35 
0  1 (2%) 
≤1  39 (85%) 
1 - ≤2  6 (13%) 
≥2  0 (0%) 
CAV 
  Grade 0 (absence) 
  Grade 1 (mild) 
 
 23 (50%) 










  Grade 2 (moderate)   
  Grade 3 (severe) 
 5 (11%) 
 1 (2%) 
 Immunosuppressive regimen 
 Prednisone 
 Mycophenolic acid  





 39 (85%) 
 5 (11%) 
 34 (74%) 
 12 (26%) 
 Cardio-vascular medication 
 ACE inhibitor 
 ARB 
 Diuretics 






 23 (50%) 
 17 (37%) 
 2 (4%) 
 12 (26%) 
 23 (50%) 
 39 (85%) 
Mean±SD or frequency and the proportion of the group, n(%) are displayed. CTx, Cardiac 
transplantation; CMP, Cardiomyopathy; ACE, Angiotensin converting enzyme, ARB, Angiotensin 
receptor blocker; CCB, Calcium channel blocker; eGFR, Estimated glomerular filtration rate. 
¥ includes rhumatismal, valvular, noncompaction, hypertrophic, congenital, restrictive and 
peripartum cardiomyopathies. *eGFR <45ml/min/1.73m2 was a predefined exclusion criterion due 












TABLE 3. CMR characteristics of CTx patients and healthy controls. 





Left Ventricular Function    
LV Ejection Fraction (%) 59 ± 7 63 ± 5 0.014 
Cardiac Index (L/min/m2) 2.9 ± 0.6 3.2 ± 0.7 0.042 
LV End-Diastolic Volume (mL) 122 ± 29 151 ± 31 <0.001 
LV End-Diastolic Volume index (mL/m2) 67 ± 28 78 ± 12 0.066 
LV End-Systolic Volume (mL) 51 ± 18 57 ± 15 0.160 
LV End-Systolic Volume index (mL/m2) 29 ± 18 29 ± 7 1.000 
LV Stroke Volume (mL) 71 ± 16 95 ± 19 <0.001 
LV stroke volume index (mL/m2) 39 ± 12 49 ± 7 <0.001 
LV mass (g) 100 ± 28 115 ± 26 0.047 
LV mass index (g/m2) 56 ± 33 59 ± 10 0.666 
    
Left Ventricular Tissue Characterization    
Native T1 (ms) 1206 ± 42 1175 ± 26 0.001 
   Patients presenting with native T1 >1227ms* 10 (21%) -  
Extracellular volume (%) 26.7 ± 3.0 23.1 ± 2.4 <0.001 
   Patients presenting with ECV >27.9%* 13 (28%) -  
Quantification of regional fibrosis (% of 
analysed mass) 
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    Patients presenting with regional fibrosis 
(LGE) 
25 (54%) -  
T2 STIR ratio 1.80 ± 0.31 -  
   Patients presenting with T2 STIR ratio >2.0 6 (13%) -  
Mean±SD or frequency and the proportion of the group, n(%) are displayed for CMR 
measurements. *The reference range for the T1 and ECV measurements were obtained from the 
mean±2SD of the presented control population. CTX= cardiac transplantation; ECV=extracellular 
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TABLE 4. OS-CMR and potential confounders. 





Sex (female) 2.6±4.5 2.9±1.8 0.838 
Gender Mismatch 2.9±4.2 1.6±4.5 0.452 
Hypertension  2.4±5.1 2.7±3.6 0.815 
Diabetes 2.1±4.5 4.0±2.8 0.200 
Dyslipidemia 2.5±5.3 2.7±3.5 0.914 
Smoking 2.6±4.3 2.9±2.8 0.917 
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TABLE 5. Linear association of OS-CMR in CTx. 
   r P value 
Characteristics   
Recipient age 0.205 0.210 
Graft age -0.293 0.070 
Time since transplant (years) 0.053 0.749 
Ischemic time (minutes) -0.168 0.307 
eGFR -0.057 0.730 
   
Left Ventricular Function   
LV ejection fraction (%) 0.172 0.309 
Cardiac index (L/min/m2) -0.162 0.785 
LV end-diastolic volume index (mL/m2) -0.445 0.007 
LV end-systolic volume index (mL/m2) -0.327 0.055 
LV stroke volume index (mL/m2) -0.336 0.049 
LV mass index (g/m2) 0.017 0.921 
   
Left Ventricular Tissue Characterization   
Native T1 (ms) -0.074 0.658 
Extracellular volume (%) -0.352 0.030 
LGE extent (%) -0.103 0.543 
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